Infar Plans Slew Of Launches

Infar (India) Ltd intends to launch a host of new products under its formulation business unit, Organon. It also plans to launch some of its existing products in new value-added packs to give sales a fillip.

The company will launch an anti-depressant towards the end of this year and some contraceptive drugs within a year. "The anti-depressant has found great response in the UK and US markets," said Jagdish Singh, marketing manager, Infar.

"The formulation business in India grew 17 per cent last year, which, compared to our growth worldwide, is disappointing," said F Burmeister, joint managing director, Infar (India) Ltd. "The market in India for the anti-depressants is vibrant and should boost our business," Burmeister said.

 

The company will also launch existing products in new packaging. Some injectables will be packaged with sterilised syringes and needles. They will be priced marginally higher.

"The company will absorb a part of the cost," Singh said. Infar has launched two hormone replacement therapy (HRT) drugs, Sandrema Gel and Orgamed, this year. HRT is a key area for the company. The company is withdrawing from its business in gastrointestinal drugs. At the company's annual general meeting here yesterday, managing director A V Iyengar said, "These are not our core competencies and these are cheap drugs which have many substitutes."